- decision psychology
- preferences/values
- mathematical models
- calibration/validation
- approaches and applications
- decision analysis
- risk analysis
- benefit-cost analysis
- cost-effectiveness analysis
- technology assessment
- operations research
- chronic disease/risk
- health systems
- policy/regulation
- global
- north america
- europe
Resources Repository
-
ArticlePublication 2016UHC for Mental, Neurological, and Substance Use Disorders: An Extended CEA
This study uses extended cost effectiveness analysis (ECEA) to analyze the impacts of universal public …
This study uses extended cost effectiveness analysis (ECEA) to analyze the impacts of universal public finance (UPF) on epilepsy, schizophrenia, and depression in India and Ethiopia. The Ethiopian government has launched a National Mental Health Strategy which explicitly recognizes the importance of an efficient, equitable scale-up of mental health care within a broader, ongoing effort to increase levels of health insurance in the general population. The analyses show that enhanced coverage of effective treatment leads…
Cost-Effectiveness Analysis | Global | Health Systems | Priority Setting/Ethics | Mental Health | Social Determinants | Economics/Finance | Health/Medicine -
ArticlePublication 2016Using Top-Down and Bottom-Up Costing Approaches in LMICs
In the absence of routine cost data collection, estimating the incremental costs of scaling-up novel …
In the absence of routine cost data collection, estimating the incremental costs of scaling-up novel technologies in low-income and middle-income countries is a methodologically challenging and substantial empirical undertaking. Using the example of costing the scale-up of Xpert Mycobacterium tuberculosis (MTB)/resistance to riframpicin (RIF) in South Africa, the authors estimate costs, by applying two distinct approaches of bottom-up and top-down costing, together with an assessment of processes and capacity. The unit costs measured using the…
Cost-Effectiveness Analysis | Global | Health Systems | Costing Methods | Infectious Diseases | Economics/Finance | Health/Medicine -
ArticlePublication 2016Using Cost-Effectiveness Evidence to Inform Health Service Provision
This article discusses three challenges of using cost-effectiveness thresholds to inform whether a third-party payer …
This article discusses three challenges of using cost-effectiveness thresholds to inform whether a third-party payer will fund a particular service. First, how is the appropriate cost-effectiveness threshold - or threshold range - to be determined? (And should there be a single threshold or multiple thresholds?) Second, how can the valuation of health benefits be refined to better capture the value of treatments to patients and to the economy as a whole? Third, how should a…
Cost-Effectiveness Analysis | Global | Policy/Regulation | Priority Setting/Ethics | Evidence Synthesis | Health/Medicine -
ArticlePublication 2016Defining a Health Benefits Package: What Are the Necessary Processes?
There is immense interest worldwide in the notion of universal health coverage. A major policy …
There is immense interest worldwide in the notion of universal health coverage. A major policy focus in moving toward universal health coverage has been on the key policy question: what services should be made available and under what conditions? This article focuses on how a feasible set of universal health coverage services can be explicitly defined to create what is commonly known as a “health benefits package”, a set of services that can be feasibly financed…
Cost-Effectiveness Analysis | Global | Health Systems | Priority Setting/Ethics | Culture/Society | Economics/Finance | Government/Law | Health/Medicine -
Tutorial/PrimerPublication, Teaching Resource 2016Distributional Cost-Effectiveness Analysis: A Tutorial
This tutorial explains distributional cost-effectiveness analysis as a framework for incorporating health inequality concerns into …
This tutorial explains distributional cost-effectiveness analysis as a framework for incorporating health inequality concerns into the economic evaluation of health sector interventions. Using an illustrative example comparing alternative ways of implementing the National Health Service (NHS) Bowel Cancer Screening Programme the authors describe the technical details of how to conduct distributional cost-effectiveness analysis. The 2 key stages are 1) modeling social distributions of health associated with different interventions, and 2) evaluating social distributions of health…
Cost-Effectiveness Analysis | Europe | Chronic Disease/Risk | Priority Setting/Ethics -
ReviewPublication 2016Review: CEA for Maternal, Newborn, Child Health
This chapter summarizes the findings of a systematic search of the cost-effectiveness literature on interventions …
This chapter summarizes the findings of a systematic search of the cost-effectiveness literature on interventions to improve reproductive, maternal, newborn, and child health. Interventions for newborn health, treatment of febrile illness, immunization against preventable diseases, and micronutrient interventions remain among the most cost-effective and affordable. Other studies explore how to provide existing interventions using new platforms to increase outreach or decrease cost per person covered, or both. Interventions provided in the community may achieve both purposes to…
Cost-Effectiveness Analysis | Global | Health Systems | Priority Setting/Ethics | Costing Methods | Infectious Diseases | Maternal/Reproductive Health | Child/Nutrition | Education/Labor | Health/Medicine -
ArticlePublication 2015Achieving a 'Grand Convergence' in Global Health
The Commission on Investing in Health published its report, GlobalHealth2035, in 2013, estimating an investment …
The Commission on Investing in Health published its report, GlobalHealth2035, in 2013, estimating an investment case for a grand convergence in health outcomes globally. In support of the drafting of the Sustainable Development Goals (SDGs), this paper presents estimates of what the grand convergence investment case might achieve—and what investment would be required—by 2030. The authors start with a country-based (bottom-up) analysis of the costs and impact of…!--?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /-->
Cost-Effectiveness Analysis | Global | Health Systems | Costing Methods | Health Outcomes | Global Governance | Economics/Finance | Health/Medicine | Science/Technology -
Tutorial/PrimerPublication, Teaching Resource 2015White Paper: Retrospective Benefit-Cost Analysis
In this article the authors consider how benefit-cost analysis can be used retrospectively to promote …
In this article the authors consider how benefit-cost analysis can be used retrospectively to promote understanding of the impacts after a policy is implemented. Serving as a brief primer, the authors propose that analysis can be useful for identifying needed reforms as well as in improving the conduct of future prospective analyses. The major challenges relate to estimating what would have occurred in the absence of the policy and separating the effects of the policy…
Benefit-Cost Analysis | North America | Policy/Regulation | Priority Setting/Ethics | Social Determinants | Environmental Health | Culture/Society | Economics/Finance | Government/Law | College | Graduate | Doctoral | Critical Thinking/Analysis | Policy Translation -
ArticlePublication 2015Cost-Effectiveness & Budget Impact of Hepatitis C Virus Treatment with Sofosbuvir & Ledipasvir in the U.S.
This study evaluates the cost-effectiveness and budget impact of sofosbuvir and ledipasvir for treating chronic …
This study evaluates the cost-effectiveness and budget impact of sofosbuvir and ledipasvir for treating chronic hepatitis C virus (HCV) infection compared to the old standard of care (oSOC). Using a microsimulation model based on HCV natural history, data from published literature, and a third-party payer perspective, the analysis considers treatment-naive and treatment-experienced HCV populations in the United States over a lifetime horizon. Sofosbuvir-based therapies are found to add 0.56 quality-adjusted life-years (QALYs) relative to oSOC,…
Cost-Effectiveness Analysis | North America | Chronic Disease/Risk | Microsimulation | Infectious Diseases | Health/Medicine